but also some positive studies that suggest TIGIT may have a role to play in some cancers. Novartis also partners BeiGene on PD-1 inhibitor tislelizumab, a drug that is already approved in China ...

with other TIGIT inhibitors still under development, including domvanalimab, rilvegostomig, and belrestotug. Govindan also said that not all TIGIT inhibitors are the same and that there is a ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

The combination of Merck & Co’s PD-1 inhibitor Keytruda with experimental TIGIT inhibitor vibostolimab has generated disappointing results in a mid-stage lung cancer trial. The open-label ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab ... and colleagues noted that anti-CTLA-4-based dual immune checkpoint inhibitor regimens have "revolutionized the treatment paradigm ...

In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody ... non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective ...

These data support the potential for casdatifan to be a best-in-class HIF-2a inhibitor for the treatment ... Domvanalimab (Fc-silent anti-TIGIT antibody) plus Zimberelimab (anti-PD-1 antibody ...

In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody ... non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective ...

The company’s pipeline, particularly its HIF2alpha inhibitor casdatifan and TIGIT programs, has positioned it as a potential leader in the oncology space. This comprehensive analysis examines Arcus ...